Sökning: L773:1525 0024 >
A novel TARP-promot...
-
Cheng, Wing-ShingUppsala universitet,Enheten för klinisk immunologi
(författare)
A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer
- Artikel/kapitelEngelska2004
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2004
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-92861
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-92861URI
-
https://doi.org/10.1016/j.ymthe.2004.05.022DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
TARP (T cell receptor gamma-chain alternate reading frame protein) is a protein that in males is uniquely expressed in prostate epithelial cells and prostate cancer cells. We have previously shown that the transcriptional activity of a chimeric sequence comprising the TARP promoter (TARPp) and the PSA enhancer (PSAe) is strictly controlled by testosterone and highly restricted to cells of prostate origin. Here we report that a chimeric sequence comprising TARPp and the PSMA enhancer (PSMAe) is highly active in testosterone-deprived prostate cancer cells, while a regulatory sequence comprising PSAe, PSMAe, and TARPp (PPT) has high prostate-specific activity both in the presence and in the absence of testosterone. Therefore, the PPT sequence may, in a gene therapy setting, be beneficial to prostate cancer patients that have been treated with androgen withdrawal. A recombinant adenovirus vector with the PPT sequence, shielded from interfering adenoviral sequences by the mouse H19 insulator, yields high and prostate-specific transgene expression both in cell cultures and when prostate cancer, PC-346C, tumors were grown orthotopically in nude mice. Intravenous virus administration reveals both higher activity and higher selectivity for the insulator-shielded PPT sequence than for the immediate-early CMV promoter. Therefore, we believe that an adenovirus with therapeutic gene expression controlled by an insulator-shielded PPT sequence is a promising candidate for gene therapy of prostate cancer.
Ämnesord och genrebeteckningar
-
Adenoviridae/*genetics
-
Animals
-
Cell Line; Tumor
-
Enhancer Elements (Genetics)/genetics
-
Gene Expression Regulation; Neoplastic
-
Gene Therapy/*methods
-
Genes; Reporter/genetics
-
Genetic Vectors/genetics
-
Humans
-
Insulator Elements/genetics
-
Luciferases/analysis/genetics
-
Male
-
Mice
-
Neoplasms; Hormone-Dependent/genetics/*metabolism/therapy
-
Nuclear Proteins/*genetics
-
Promoter Regions (Genetics)/*genetics
-
Prostatic Neoplasms/genetics/*metabolism/therapy
-
Research Support; Non-U.S. Gov't
-
Testosterone/metabolism
-
MEDICINE
-
MEDICIN
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Kraaij, Robert
(författare)
-
Nilsson, BerithUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)benil498
(författare)
-
van der Weel, Laura
(författare)
-
de Ridder, Corrina M.A.
(författare)
-
Tötterman, Thomas H.Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)thomtott
(författare)
-
Essand, MagnusUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)magnessa
(författare)
-
Uppsala universitetEnheten för klinisk immunologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Molecular Therapy: Elsevier BV10:2, s. 355-3641525-00161525-0024
Internetlänk
Hitta via bibliotek
Till lärosätets databas